ERBB2 and breast carcinoma: In the neoadjuvant phase, the analysis of pCR (absolute difference = 11.0%; OR = 1.33; 95% CI, 1.08–1.63; P = 0.006) (Fig. 2a and b) showed that HER2+ breast cancer patients receiving pertuzumab achieved a greater benefit from H + P compared with that achieved from H. Peter Beitsch et al. reported a higher pCR rate than that obtained in other studies [10], and his study outcome showed that the pCR in the H + P group was higher than that in the H group (57.0 and 40.0%, respectively), with an absolute difference of 17.0%.